Skip to main content

Table 7 Rank for 28 patients at the ten positions available, when all outcomes were included in the analysis

From: Rapid methods including network meta-analysis to produce evidence in clinical decision support: a decision analysis

 

Rank 1

Rank 2

Rank 3

Rank 4

Rank 5

Rank 6

Rank 7

Rank 8

Rank 9

Rank 10

PLB

0

2

0

0

0

1

6

5

2

12

OLZ

6

10

5

1

1

1

4

0

0

0

LIT

0

0

2

20

4

2

0

0

0

0

RISlai

0

0

0

0

0

2

6

4

8

8

LAM

5

3

0

4

11

4

1

0

0

0

LITVAL

6

5

10

1

4

2

0

0

0

0

QTP

11

7

7

0

1

1

0

1

0

0

VAL

0

0

3

2

4

11

4

4

0

0

IMI

0

1

1

0

0

1

3

8

10

4

LITIMI

0

0

0

0

3

3

4

6

8

4

  1. PLB placebo, OLZ olanzapine, LIT lithium, RISlai risperidone LAI, LAM lamotrigine, LITVAL lithium + valproate, QTP quetiapine, VAL valproate, IMI imipramine, LITIMI lithium + imipramine